Liothyronine

DRUG INFORMATION

  ADULT
    - Administer Liothyronine Sodium Tablets, USP orally once daily. 2.2 Recommended
      Dosage for Hypothyroidism Adults The recommended starting dosage is 25 mcg orally
      once daily.
      Source: US FDA label for liothyronine (Liothyronine Sodium), section 'dosage and
      administration', retrieved 2026-08-29
    - Increase the dose by 25 mcg daily every 1 or 2 weeks, if needed.
      Source: US FDA label for liothyronine (Liothyronine Sodium), section 'dosage and
      administration', retrieved 2026-08-29
    - The usual maintenance dose is 25 mcg to 75 mcg once daily.
      Source: US FDA label for liothyronine (Liothyronine Sodium), section 'dosage and
      administration', retrieved 2026-08-29

  CHILD
    - The initial dose of Liothyronine Sodium Tablets, USP varies with age and body
      weight. Dosing adjustments are based on an assessment of the individual patient's
      clinical and laboratory parameters [see Dosage and Administration (2.3 , 2.4 )].
      In pediatric patients in whom a diagnosis of permanent hypothyroidism has not been
      established, discontinue thyroid hormone for a trial period, but only after the
      child is at least 3 years of age.
      Source: US FDA label for liothyronine (Liothyronine Sodium), section 'pediatric
      use', retrieved 2026-08-29
    - Pediatric Patients The recommended starting dosage is 5 mcg once daily, with a 5
      mcg increase every 3 to 4 days until the desired response is achieved.
      Source: US FDA label for liothyronine (Liothyronine Sodium), section 'dosage and
      administration', retrieved 2026-08-29
    - Infants a few months old may require 20 mcg once daily for maintenance.
      Source: US FDA label for liothyronine (Liothyronine Sodium), section 'dosage and
      administration', retrieved 2026-08-29

  RENAL IMPAIRMENT
    - No kidney-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for liothyronine (Liothyronine
      Sodium), retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - No liver-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for liothyronine (Liothyronine
      Sodium), retrieved 2026-08-29

  PREGNANCY
    - Risk Summary Experience with liothyronine use in pregnant women, including data
      from post-marketing studies, have not reported increased rates of major birth
      defects or miscarriages (see Data ).
      Source: US FDA label for liothyronine (Liothyronine Sodium), section 'pregnancy',
      retrieved 2026-08-29
    - There are risks to the mother and fetus associated with untreated hypothyroidism
      in pregnancy.
      Source: US FDA label for liothyronine (Liothyronine Sodium), section 'pregnancy',
      retrieved 2026-08-29
    - Since TSH levels may increase during pregnancy, TSH should be monitored and
      liothyronine sodium dosage adjusted during pregnancy (see Clinical Considerations
      ).
      Source: US FDA label for liothyronine (Liothyronine Sodium), section 'pregnancy',
      retrieved 2026-08-29

  BREASTFEEDING
    - Data from post-marketing studies have not reported increased rates of fetal
      malformations, miscarriages, or other adverse maternal or fetal outcomes
      associated with liothyronine use in pregnant women. 8.2 Lactation Risk Summary
      Limited published studies report that liothyronine is present in human milk.
      Source: US FDA label for liothyronine (Liothyronine Sodium), section 'use in
      specific populations', retrieved 2026-08-29
    - However, there is insufficient information to determine the effects of
      liothyronine on the breastfed infant and no available information on the effects
      of liothyronine on milk production.
      Source: US FDA label for liothyronine (Liothyronine Sodium), section 'use in
      specific populations', retrieved 2026-08-29
    - The developmental and health benefits of breastfeeding should be considered along
      with the mother's clinical need for liothyronine sodium and any potential adverse
      effects on the breastfed infant from liothyronine sodium or from the underlying
      maternal condition. 8.4 Pediatric Use The initial dose of Liothyronine Sodium
      Tablets, USP varies with age and body weight.
      Source: US FDA label for liothyronine (Liothyronine Sodium), section 'use in
      specific populations', retrieved 2026-08-29